-
Je něco špatně v tomto záznamu ?
Synthesis, antiproliferative activity in cancer cells and DNA interaction studies of [Pt(cis-1,3-diaminocycloalkane)Cl2] analogs
JD. Hoeschele, J. Kasparkova, H. Kostrhunova, O. Novakova, J. Pracharova, P. Pineau, V. Brabec
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antitumorózní látky chemická syntéza farmakologie MeSH
- apoptóza účinky léků MeSH
- cisplatina farmakologie normy MeSH
- cyklické uhlovodíky chemická syntéza MeSH
- DNA chemie MeSH
- glutathion chemie MeSH
- léky antitumorózní - screeningové testy MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- organokovové sloučeniny chemická syntéza farmakologie MeSH
- permeabilita buněčné membrány MeSH
- platina chemie MeSH
- proliferace buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The search for more effective platinum anticancer drugs has led to the design, synthesis, and preclinical testing of hundreds of new platinum complexes. This search resulted in the recognition and subsequent FDA approval of the third-generation Pt(II) anticancer drug, [Pt(1,2-diaminocyclohexane)(oxalate)], oxaliplatin, as an effective agent in treating colorectal and gastrointestinal cancers. Another promising example of the class of anticancer platinum(II) complexes incorporating the Pt(1,n-diaminocycloalkane) moiety is kiteplatin ([Pt(cis-1,4-DACH)Cl2], DACH = diaminocyclohexane). We report here our progress in evaluating the role of the cycloalkyl moiety in these complexes focusing on the synthesis, characterization, evaluation of the antiproliferative activity in tumor cells and studies of the mechanism of action of new [Pt(cis-1,3-diaminocycloalkane)Cl2] complexes wherein the cis-1,3-diaminocycloalkane group contains the cyclobutyl, cyclopentyl, and cyclohexyl moieties. We demonstrate that [Pt(cis-1,3-DACH)Cl2] destroys cancer cells with greater efficacy than the other two investigated 1,3-diamminocycloalkane derivatives, or cisplatin. Moreover, the investigated [Pt(cis-1,3-diaminocycloalkane)Cl2] complexes show selectivity toward tumor cells relative to non-tumorigenic normal cells. We also performed several mechanistic studies in cell-free media focused on understanding some early steps in the mechanism of antitumor activity of bifunctional platinum(II) complexes. Our data indicate that reactivities of the investigated [Pt(cis-1,3-diaminocycloalkane)Cl2] complexes and cisplatin with glutathione and DNA binding do not correlate with antiproliferative activity of these platinum(II) complexes in cancer cells. In contrast, we show that the higher antiproliferative activity in cancer cells of [Pt(cis-1,3-DACH)Cl2] originates from its highest hydrophobicity and most efficient cellular uptake.
Department of Chemistry Eastern Michigan University Ypsilanti MI 48197 USA
Institute of Biophysics Czech Academy of Sciences Kralovopolska 135 61265 Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020194
- 003
- CZ-PrNML
- 005
- 20210830101825.0
- 007
- ta
- 008
- 210728s2020 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00775-020-01809-9 $2 doi
- 035 __
- $a (PubMed)32851480
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Hoeschele, James D $u Department of Chemistry, Eastern Michigan University, Ypsilanti, MI, 48197, USA
- 245 10
- $a Synthesis, antiproliferative activity in cancer cells and DNA interaction studies of [Pt(cis-1,3-diaminocycloalkane)Cl2] analogs / $c JD. Hoeschele, J. Kasparkova, H. Kostrhunova, O. Novakova, J. Pracharova, P. Pineau, V. Brabec
- 520 9_
- $a The search for more effective platinum anticancer drugs has led to the design, synthesis, and preclinical testing of hundreds of new platinum complexes. This search resulted in the recognition and subsequent FDA approval of the third-generation Pt(II) anticancer drug, [Pt(1,2-diaminocyclohexane)(oxalate)], oxaliplatin, as an effective agent in treating colorectal and gastrointestinal cancers. Another promising example of the class of anticancer platinum(II) complexes incorporating the Pt(1,n-diaminocycloalkane) moiety is kiteplatin ([Pt(cis-1,4-DACH)Cl2], DACH = diaminocyclohexane). We report here our progress in evaluating the role of the cycloalkyl moiety in these complexes focusing on the synthesis, characterization, evaluation of the antiproliferative activity in tumor cells and studies of the mechanism of action of new [Pt(cis-1,3-diaminocycloalkane)Cl2] complexes wherein the cis-1,3-diaminocycloalkane group contains the cyclobutyl, cyclopentyl, and cyclohexyl moieties. We demonstrate that [Pt(cis-1,3-DACH)Cl2] destroys cancer cells with greater efficacy than the other two investigated 1,3-diamminocycloalkane derivatives, or cisplatin. Moreover, the investigated [Pt(cis-1,3-diaminocycloalkane)Cl2] complexes show selectivity toward tumor cells relative to non-tumorigenic normal cells. We also performed several mechanistic studies in cell-free media focused on understanding some early steps in the mechanism of antitumor activity of bifunctional platinum(II) complexes. Our data indicate that reactivities of the investigated [Pt(cis-1,3-diaminocycloalkane)Cl2] complexes and cisplatin with glutathione and DNA binding do not correlate with antiproliferative activity of these platinum(II) complexes in cancer cells. In contrast, we show that the higher antiproliferative activity in cancer cells of [Pt(cis-1,3-DACH)Cl2] originates from its highest hydrophobicity and most efficient cellular uptake.
- 650 _2
- $a antitumorózní látky $x chemická syntéza $x farmakologie $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a permeabilita buněčné membrány $7 D002463
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a cisplatina $x farmakologie $x normy $7 D002945
- 650 _2
- $a DNA $x chemie $7 D004247
- 650 _2
- $a léky antitumorózní - screeningové testy $7 D004354
- 650 _2
- $a glutathion $x chemie $7 D005978
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a cyklické uhlovodíky $x chemická syntéza $7 D006844
- 650 _2
- $a organokovové sloučeniny $x chemická syntéza $x farmakologie $7 D009942
- 650 _2
- $a platina $x chemie $7 D010984
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kasparkova, Jana $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, 61265, Brno, Czech Republic
- 700 1_
- $a Kostrhunova, Hana $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, 61265, Brno, Czech Republic
- 700 1_
- $a Novakova, Olga $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, 61265, Brno, Czech Republic
- 700 1_
- $a Pracharova, Jitka $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, 61265, Brno, Czech Republic
- 700 1_
- $a Pineau, Paul $u Department of Chemistry, Eastern Michigan University, Ypsilanti, MI, 48197, USA
- 700 1_
- $a Brabec, Viktor $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, 61265, Brno, Czech Republic. brabec@ibp.cz
- 773 0_
- $w MED00005752 $t Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry $x 1432-1327 $g Roč. 25, č. 6 (2020), s. 913-924
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32851480 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101825 $b ABA008
- 999 __
- $a ok $b bmc $g 1690897 $s 1140640
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 25 $c 6 $d 913-924 $e 20200826 $i 1432-1327 $m JBIC, Journal of biological inorganic chemistry $n J Biol Inorg Chem $x MED00005752
- LZP __
- $a Pubmed-20210728